2
Announcements
Trials
Browse
Landscape
Status
Unknown
2
Completed
1
Sponsor Class
INDUSTRY
3
Study Type
Observational
3
Sponsor
Conditions
Pain
27
Neoplasms
20
Cancer Pain
10
Colonic Neoplasms
7
Breakthrough Pain
7
Agnosia
7
Breast Neoplasms
5
Rectal Neoplasms
4
Prostatic Neoplasms
4
Lung Neoplasms
4
Head and Neck Neoplasms
4
Chronic Pain
4
Urinary Bladder Neoplasms
3
Sarcoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Pain, Postoperative
3
Lymphoma, Follicular
3
Breakthrough Cancer Pain
3
Waldenstrom Macroglobulinemia
2
Uterine Cervical Neoplasms
2
Thrombocythemia, Essential
2
Sezary Syndrome
2
Primary Myelofibrosis
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Polycythemia Vera
2
Pleural Effusion, Malignant
2
Pdgfra-Associated Chronic Eosinophilic Leukemia
2
Myeloproliferative Disorders
2
Mycosis Fungoides
2
Interventions
Fentanyl
3
Nasal Sprays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Breakthrough Cancer Pain
×
Fentanyl
×
Clear all
NCT03895762
2022-05-05
OASIS
A.Menarini Asia-Pacific Holdings Pte Ltd
Completed
143 enrolled
NCT01693328
2014-01-15
Qualipec
Archimedes Development Ltd
Unknown
300 enrolled
NCT01698645
2013-07-11
Qualipec
Archimedes Development Ltd
Unknown
150 enrolled